news
Breakthrough in fighting liver disease
3 September 2015 | By Victoria White
The University of Brighton has announced it is sharing in a €5.9m EU grant to support the development of a new treatment for chronic liver disease...
List view / Grid view
Liver disease
news
MRC scientists regrow liver from liver stem cells
21 July 2015 | By Victoria White
Medical Research Council (MRC) scientists have repaired a damaged liver in a mouse by transplanting liver stem cells grown in the laboratory...
news
Protein from Vibrio vulnificus can inhibit tumour cell growth by cutting the protein Ras
9 June 2015 | By Victoria White
Scientists have discovered that a toxin secreted by Vibrio vulnificus has potential to prevent the growth of tumours by cutting the protein Ras...
news
Alnylam files Clinical Trial Application for ALN-AAT for the treatment of Alpha-1 Liver Disease
21 May 2015 | By Victoria White
Alnylam has filed a Clinical Trial Application to initiate a Phase 1/2 clinical trial with ALN-AAT for the treatment of alpha-1 liver disease...
article
The promise of induced pluripotent stem cells for liver disease, toxicology and drug discovery
We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
news
Partnering for Cure programme announces new winning projects designed to investigate novel ways to cure viral diseases
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
news
The end of hepatitis C?
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
news
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90%
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
news
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...